Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IGMS IGM Biosciences	$1.22 +0.8%	$1.24	$0.92 ▼ $22.50	$72.33M	0.52	303,187 shs	72,306 shs
IMUX Immunic	$0.71 +1.3%	$0.91	$0.56 ▼ $2.11	$67.20M	1.48	957,121 shs	1.29 million shs
INCR InterCure	$1.49 +0.7%	$1.52	$1.17 ▼ $2.62	$67.45M	1.22	26,008 shs	48,097 shs
LGVN Longeveron	$1.30 +2.4%	$1.38	$1.14 ▼ $6.40	$18.96M	0.22	1.39 million shs	144,270 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IGMS IGM Biosciences	+0.83%	+4.27%	0.00%	-1.61%	-81.76%
IMUX Immunic	+1.30%	-5.28%	-20.18%	-40.80%	-27.56%
INCR InterCure	+0.68%	+0.34%	-3.87%	+5.67%	-31.96%
LGVN Longeveron	+2.36%	+7.44%	-2.99%	-17.72%	-23.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IGMS IGM Biosciences	4.1966 of 5 stars	3.0	4.0	4.6	1.0	3.3	0.6
IMUX Immunic	3.0645 of 5 stars	3.6	3.0	0.0	2.5	2.5	0.6
INCR InterCure	0.3781 of 5 stars	0.0	3.0	0.0	1.9	0.0	0.6
LGVN Longeveron	3.6919 of 5 stars	3.6	5.0	0.0	2.8	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IGMS IGM Biosciences	1.90	Reduce	$5.50	350.82% Upside
IMUX Immunic	3.25	Buy	$11.60	1,532.88% Upside
INCR InterCure	0.00	N/A	N/A	N/A
LGVN Longeveron	3.25	Buy	$8.67	566.67% Upside

Current Analyst Ratings Breakdown

Latest LGVN, IGMS, INCR, and IMUX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00
5/23/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	IMUX Immunic	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/1/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/30/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/16/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/15/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/10/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IGMS IGM Biosciences	$2.68M	27.21	N/A	N/A	$0.82 per share	1.49
IMUX Immunic	N/A	N/A	N/A	N/A	$0.20 per share	N/A
INCR InterCure	$64.55M	1.05	N/A	N/A	$2.36 per share	0.63
LGVN Longeveron	$2.39M	8.12	N/A	N/A	$1.47 per share	0.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IGMS IGM Biosciences	-$195.79M	-$3.27	N/A	N/A	N/A	-7,417.79%	-317.97%	-71.43%	8/13/2025 (Estimated)
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-326.95%	-181.34%	8/6/2025 (Estimated)
INCR InterCure	-$18.32M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)
LGVN Longeveron	-$15.97M	-$6.28	N/A	N/A	N/A	-760.72%	-85.07%	-70.74%	8/13/2025 (Estimated)

Latest LGVN, IGMS, INCR, and IMUX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/13/2025	Q1 2025	IGMS IGM Biosciences	-$0.41	-$0.86	-$0.45	-$0.86	$4.25 million	$0.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IGMS IGM Biosciences	N/A	5.71	5.71
IMUX Immunic	N/A	0.74	0.74
INCR InterCure	0.34	1.73	1.18
LGVN Longeveron	N/A	5.61	5.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IGMS IGM Biosciences	42.79%
IMUX Immunic	51.82%
INCR InterCure	8.34%
LGVN Longeveron	10.01%

Insider Ownership

Company	Insider Ownership
IGMS IGM Biosciences	57.00%
IMUX Immunic	4.60%
INCR InterCure	0.24%
LGVN Longeveron	11.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IGMS IGM Biosciences	190	59.78 million	25.70 million	Optionable
IMUX Immunic	70	95.82 million	91.41 million	Optionable
INCR InterCure	350	45.57 million	45.46 million	Optionable
LGVN Longeveron	20	14.93 million	13.26 million	Not Optionable

LGVN, IGMS, INCR, and IMUX Headlines

Recent News About These Companies

Longeveron Inc. Appoints Than Powell as Chief Business Officer to Lead Partnering and International Strategy

June 26 at 9:24 AM | quiverquant.comQ

Longeveron® Appoints Than Powell as Chief Business Officer

June 26 at 9:05 AM | globenewswire.com

LGVN Announces Pivotal Test Update

June 24 at 8:46 PM | msn.com

Longeveron Inc. Completes Enrollment for Phase 2b ELPIS II Trial Evaluating Laromestrocel for Hypoplastic Left Heart Syndrome, With Results Expected in Q3 2026

June 24 at 6:43 AM | quiverquant.comQ

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

June 24 at 6:30 AM | globenewswire.com

Longeveron Inc. CEO Wa’el Hashad to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 11, 2025 | nasdaq.com

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 9, 2025 | globenewswire.com

Longeveron Inc. (NASDAQ:LGVN) Director Sells $13,000.00 in Stock

June 3, 2025 | insidertrades.com

Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely

May 29, 2025 | finance.yahoo.com

Longeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International Convention

May 22, 2025 | nasdaq.com

Longeveron Inc.

May 21, 2025 | marketwatch.com

Longeveron® to Attend BIO International Convention 2025

May 20, 2025 | globenewswire.com

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 12, 2025 | globenewswire.com

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

LGVN Entering Crucial Period in Great Shape

May 9, 2025 | msn.com

Roth MKM Remains a Buy on Longeveron (LGVN)

May 9, 2025 | theglobeandmail.com

Longeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of Earnings

May 9, 2025 | finance.yahoo.com

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | finance.yahoo.com

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

May 2, 2025 | globenewswire.com

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

April 23, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
New Catalysts to Drive NVIDIA’s Stock Price Even Higher
By Thomas Hughes | June 16, 2025
View New Catalysts to Drive NVIDIA’s Stock Price Even Higher
Marvell's New AI Chip Deals Capture Wall Street’s Attention
By Jeffrey Neal Johnson | June 21, 2025
View Marvell's New AI Chip Deals Capture Wall Street’s Attention
Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow
By Thomas Hughes | June 18, 2025
View Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow
Salesforce’s Stock Price Presents an Opportunity to Buy
By Thomas Hughes | May 29, 2025
View Salesforce’s Stock Price Presents an Opportunity to Buy

LGVN, IGMS, INCR, and IMUX Company Descriptions

IGM Biosciences NASDAQ:IGMS

$1.22 +0.01 (+0.83%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.16 -0.06 (-5.33%)

As of 04:00 AM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Immunic NASDAQ:IMUX

$0.71 +0.01 (+1.30%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.71 0.00 (-0.48%)

As of 04:39 AM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

InterCure NASDAQ:INCR

$1.49 +0.01 (+0.68%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$1.50 +0.01 (+0.34%)

As of 06/26/2025 07:51 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Longeveron NASDAQ:LGVN

$1.30 +0.03 (+2.36%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.30 0.00 (0.00%)

As of 04:21 AM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time